Jazz Pharmaceuticals (JAZZ) Is Up 8.5% After Q1 Profit Rebound And Ziihera Priority Review – Has The Bull Case Changed?

• In the first quarter of 2026, Jazz Pharmaceuticals reported revenue of US$1,068.9 million, up from US$897.8 million a year earlier, and turned a US$92.5 million net loss into US$293.1 million in net income, with earnings per share swinging from a loss to US$4.43 on a diluted basis.
• At the same time, the FDA accepted a Priority Review for Jazz’s Ziihera (zanidatamab-hrii) in first-line HER2-positive advanced gastric and related cancers, underscoring the company’s push to expand its oncology portfolio beyond its established neuroscience and rare disease franchises.
• With this strong quarterly profitability turnaround and Ziihera’s Priority Review in HER2-positive gastric cancer, we’ll examine how these developments reshape Jazz’s investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Jazz Pharmaceuticals Investment Narrative Recap

To own Jazz Pharmaceuticals, you need to believe it can offset looming sleep-franchise patent pressures by scaling newer oncology and rare disease assets. The sharp swing back to profitability in Q1 2026 is encouraging, but the most important near term catalyst is Ziihera’s first line HER2 positive gastric cancer review, while execution risk around replacing Xyrem and related revenues remains front and center. This latest news meaningfully raises the stakes on that oncology transition.

The FDA’s Priority Review of Ziihera’s sBLA in first line HER2 positive gastric and related cancers is the clearest link between Jazz’s recent quarter and its forward story. It connects current earnings power with a potential new oncology pillar that could diversify away from aging sleep brands. How the market responds to progress on Ziihera, alongside assets like Zepzelca and dordaviprone, will likely frame how investors weigh the near term patent and pricing risks.

Yet for investors, the real tension is that while Ziihera’s progress looks promising, the clock is still ticking toward potential generic competition that could materially affect Jazz’s…

Read the full narrative on Jazz Pharmaceuticals (it’s free!)

Jazz Pharmaceuticals’ narrative projects $5.2 billion revenue and $1.3 billion earnings by 2029. This requires 7.0% yearly revenue growth and about a $1.7 billion earnings increase from -$356.1 million today.

Uncover how Jazz Pharmaceuticals’ forecasts yield a $225.53 fair value, in line with its current price.

Exploring Other Perspectives

Before this quarter, the most optimistic analysts were already banking on Jazz reaching about US$5.7 billion in revenue and US$1.3 billion in earnings by 2028, which is a far more upbeat view than consensus. With Q1 profits rebounding and Ziihera under Priority Review, those bullish expectations around oncology diversification and patent cliff resilience might now look either more achievable or overly confident, depending on how you weigh the risk that Xywav and other core drugs could still face faster erosion than expected.

Explore 5 other fair value estimates on Jazz Pharmaceuticals – why the stock might be worth 17% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Searching For A Fresh Perspective?

Opportunities like this don’t last. These are today’s most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com